Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SAFETY, PHARMACOKINETICS, AND ANTIVIRAL RESPONSE OF CD4-IMMUNOGLOBULIN-G BY INTRAVENOUS BOLUS IN AIDS AND AIDS-RELATED COMPLEX
Autore:
COLLIER AC; COOMBS RW; KATZENSTEIN D; HOLODNIY M; GIBSON J; MORDENTI J; IZU AE; DULIEGE AM; AMMANN AJ; MERIGAN T; COREY L;
Indirizzi:
1001 BROADWAY,SUITE 218 SEATTLE WA 98122 UNIV WASHINGTON,DEPT MED SEATTLE WA 00000 UNIV WASHINGTON,DEPT LAB MED SEATTLE WA 98195 STANFORD UNIV,DEPT MED PALO ALTO CA 94304 GENENTECH INC S SAN FRANCISCO CA 94080
Titolo Testata:
Journal of acquired immune deficiency syndromes and human retrovirology
fascicolo: 2, volume: 10, anno: 1995,
pagine: 150 - 156
SICI:
1077-9450(1995)10:2<150:SPAARO>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
RECOMBINANT SOLUBLE CD4; IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 REPLICATION INVITRO; SYNERGISTIC INHIBITION; T4 MOLECULE; INFECTION; PROTEIN; THERAPY; IMMUNOADHESIN; RETROVIRUS;
Keywords:
CD4 IMMUNOGLOBULIN; ANTIRETROVIRAL THERAPY; HIV; PHASE ONE; RECOMBINANT CD4;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
A.C. Collier et al., "SAFETY, PHARMACOKINETICS, AND ANTIVIRAL RESPONSE OF CD4-IMMUNOGLOBULIN-G BY INTRAVENOUS BOLUS IN AIDS AND AIDS-RELATED COMPLEX", Journal of acquired immune deficiency syndromes and human retrovirology, 10(2), 1995, pp. 150-156

Abstract

To assess the safety, pharmacokinetics, and antiviral effects of intravenous recombinant CD4 immunoglobulin G (CD4-IgG), a 12-week Phase One study with an optional maintenance phase was performed. Twenty-two subjects with advanced human immunodeficiency virus (HIV) infection were enrolled; 15 subjects completed the initial 12 weeks. CD4-IgG doses were 30, 100, or 300 mu g/kg weekly; 1,000 mu g/kg once, twice, or three times per week; or 3,000 mu g/kg twice weekly. Serum concentrationsof CD4-IgG increased linearly with dose, with average peak serum concentrations of 22 mu g/ml with 1,000 mu g/kg. CD4-IgG was well tolerated; one patient had self-limited tachycardia and flushing associated with CD4-IgG therapy. No changes were seen in CD4 cell counts, hematologic or coagulation studies, serum chemistries, HIV p24 antigen titers, or plasma HIV titers. No subject developed anti-CD4 antibodies. HIV isolates from five patients had IC90 values that were higher than the peak concentrations of CD4-IgG achieved in those patients. Additional studies that achieve higher CD4-IgG concentrations are necessary to evaluate the antiviral activity of this compound.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 17:04:37